Financial Data and Key Metrics Changes - The company is preparing to file a Biologics License Application (BLA) in the first half of next year, which is expected to propel growth [15][65] - The company has treated over 100 patients with its lead construct, KYV-101, and has reported no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) in compassionate use data [8][9] Business Line Data and Key Metrics Changes - KYV-101 is fully enrolled for its clinical trial in Stiff Person Syndrome (SPS) and is transitioning its pivotal trial for Myasthenia Gravis (MG) from Phase II to Phase III [3][4] - The company is also looking to file an Investigational New Drug (IND) application for KYV-102 in the second half of this year [6] Market Data and Key Metrics Changes - The market for SPS is believed to be larger than previously anticipated due to the lack of approved therapies, with a significant unmet need for effective treatments [11][21] - The company is targeting a prevalent pool of patients who are currently cycling through symptomatic therapies, indicating a substantial commercial opportunity [21][22] Company Strategy and Development Direction - The company aims to be the first CAR T company to launch in the autoimmune space, focusing on neuroimmunology diseases [5][10] - There is a strategic emphasis on capital efficiency and leveraging synergies between indications to streamline operations and enhance market access [10][23] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for KYV-101 to provide transformative effects for patients, particularly in terms of long-term durable remission [19][20] - The company is excited about upcoming data readouts for multiple sclerosis (MS) and rheumatoid arthritis (RA), which could further validate its CAR T therapies [46][47] Other Important Information - The company has a strong manufacturing success rate of over 95% and is expanding its manufacturing capacity through partnerships [50][51] - There is ongoing interest from other companies for potential partnerships based on early data, indicating a positive outlook for collaboration in the future [48] Q&A Session Summary Question: What is the expected market size for Stiff Person Syndrome? - Management believes the market has been underappreciated and that there is a significant unmet need for effective therapies, which KYV-101 aims to address [11][21] Question: How does KYV-101 differ from other therapies for SPS? - KYV-101 targets the underlying cause of the disease through complete B cell depletion, offering a chance for a long-term autoimmune reset, unlike symptomatic treatments [17][18] Question: What are the expectations for the pivotal trial in Myasthenia Gravis? - The trial is designed to include biologic-naive patients, which could position KYV-101 earlier in treatment lines, potentially changing the treatment paradigm [29][32] Question: How is the company preparing for commercial activities post-data readout? - The company is developing a pricing and market access strategy to justify a significant price for KYV-101 based on the value it brings to patients [22][23] Question: What are the upcoming milestones for the company? - Key upcoming milestones include reading out interim Phase II results for MG, initiating enrollment in the pivotal Phase III study for MG, and the readout for SPS in the first half of next year [65]

Financial Data and Key Metrics Changes - The company reported revenue of RMB 446 million for 2025, representing a 48% year-over-year growth, although the first half was impacted by supply constraints [12][14] - Revenue from Nephicon alone reached RMB 520 million in August, indicating a strong recovery from earlier supply issues [13] - Full year revenue guidance for 2025 is set between RMB 1.6 billion to RMB 1.8 billion, with Nephicon expected to contribute RMB 1.2 billion to RMB 1.4 billion [13][14] - The gross margin on a cash basis was 76.4%, slightly lower than 2024 due to price reductions after NRDL inclusion, but expected to recover above 80% in the long run [14] - The non-IFRS net loss was approximately RMB 147 million, down 31% year-over-year, indicating improved operational efficiency [14] Business Line Data and Key Metrics Changes - Nephicon generated RMB 825 million in revenue from January to August, with strong market demand leading to a significant uptick in sales after regulatory approval [4][5] - The autoimmune disease franchise, particularly Velsipiti, is progressing well with NDA reviews and expected early 2026 approval [7][8] - XERAVA in the anti-infective segment showed steady growth, with revenue increasing by 37% year-over-year [23] Market Data and Key Metrics Changes - The company aims to expand Nephicon's market coverage to 1,000 hospitals, targeting approximately 30,000 new patients [18][20] - The estimated market for IgAN in China includes about 5 million patients, with significant growth potential as the company expands its reach [19][20] - The ulcerative colitis market is projected to grow, with peak sales for Velsipiti expected to reach RMB 5 billion [34] Company Strategy and Development Direction - The company is focused on a dual strategy of commercialization and in-house discovery, with significant investments in R&D to support long-term growth [35][72] - Plans include localizing production for various products and preparing for NRDL negotiations to enhance market access [72] - The company is also exploring partnerships and in-licensing opportunities to bolster its product pipeline and market presence [76] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving operational profitability earlier than previously guided, now targeting Q4 2025 [15] - The company is optimistic about the upcoming regulatory approvals and market launches, which are expected to drive revenue growth [71][72] - Management highlighted the strong clinical data supporting their products, which positions them favorably in the market [82] Other Important Information - The company completed a strategic investment of USD 30.9 million in I Mab, becoming the largest shareholder with a 16.1% stake [12][70] - The company is advancing its proprietary mRNA technology platform, which is expected to enhance its R&D capabilities and product offerings [48][49] Q&A Session Summary Question: Peak sales for Etrasimod - Management noted that the potential for Etrasimod is higher than previously stated due to strong clinical data and an underdeveloped market, with preparations underway for commercial launch [80][82][86] Question: Development plans for EVER-one - Management confirmed that they are in the design stage for pivotal trials and are planning to initiate these studies in 2026, with ongoing discussions for potential partnerships [89][90][92]

Financial Data and Key Metrics Changes - In Q2 2025, net product revenue was $20.9 million, up from $9 million in Q1 2025, indicating strong momentum in the product launch [14][6] - The net loss for Q2 2025 was $47.9 million, reduced from a loss of $58.3 million in Q2 2024 [17] - Cash, cash equivalents, and marketable securities totaled $454.3 million at the end of Q2 2025, down from $588 million at the end of 2024 [18] Business Line Data and Key Metrics Changes - Product sales for the first six months of the launch reached $29.9 million, with a total of 46 centers authorized for the use of Ocatsol [6][7] - Cost of sales in Q2 2025 was $24.4 million, which includes costs for products delivered but not yet administered [15] - Research and development expenses decreased to $27.4 million in Q2 2025 from $36.6 million in the same period in 2024 [16] Market Data and Key Metrics Changes - The company has achieved 90% total US medical lives covered and aims to reach over 60 authorized centers by year-end [7] - The company does not expect EU sales in 2025 and 2026 due to limited resources and the need for economically viable market access [9] Company Strategy and Development Direction - The company is focused on expanding the use of Ovicell beyond adult patients with relapsed-refractory ALL and is making progress in autoimmune diseases [12][20] - The company is taking a disciplined approach to market access in Europe, evaluating country by country for economically viable launches [9][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the product's reception and the potential for increased patient enrollment as administrative adjustments are resolved by Q4 [8][30] - The company plans to release updated data from its Phase I study at the ACR meeting in October and expects to dose the first patients in several upcoming studies [20][98] Other Important Information - The company received conditional marketing authorization in the UK and from the European Commission, with ongoing market access discussions [8][9] - The company is broadening real-world experience in the US to support market access conversations elsewhere [9] Q&A Session Summary Question: What is the status of the Germany launch? - Management indicated that market access methodologies in Europe are challenging, particularly for CAR T programs, and emphasized a methodical approach to launching in different countries [24][26] Question: How will revenue recognition change with the split reimbursement? - The CFO clarified that revenue recognition has shifted to a 50/50 split between the first and second administration, with expectations for enrollment and sales to accelerate post-implementation [28][29] Question: What is the feedback from the US community regarding the product? - Management reported very positive feedback, with early reorder activity from treatment centers indicating strong acceptance [38] Question: What is the timeline for the UK and Germany launches? - Management expects potential launches in the UK by early next year, contingent on favorable negotiations, while Germany's timeline remains uncertain [65][66] Question: How many patients were treated in Q2? - Management did not provide specific numbers but indicated that the revenue can be backtracked based on therapy costs [90] Question: What is the expected data release for the lupus Phase II trial? - Management stated that it is premature to provide a timeline for data from the lupus nephritis study, as patient enrollment is just beginning [99]

Cema-cel & ALPHA3 Trial - The ALPHA3 trial is designed to predict and intervene BEFORE relapse in LBCL patients, using cema-cel as a 1L consolidation treatment for MRD+ patients[16] - Phase 1 data showed cema-cel achieved a 100% CR rate in patients with low disease burden, paving the way for ALPHA3[19] - The ALPHA3 trial aims to enroll ~240 LBCL patients in CR/PR at the end of 1L therapy with MRD across ~50 US cancer centers and additional international sites[41] - The ALPHA3 addressable population creates a ~$5 billion potential market opportunity in the US and EU5[44, 92] ALLO-329 - Phase 1 Rheumatology Basket Trial for ALLO-329 was IND cleared in Jan 2025, with trial initiation expected in mid-2025 and potential clinical and biomarker PoC data in 1H 2026[52] - ALLO-329 is a dual CD19/CD70 allogeneic CAR T with Dagger® technology, designed to maximize CAR T expansion and potentially eliminate the need for lymphodepletion[54] - The RESOLUTION basket study will address four large diseases: Lupus (SLE) with an estimated US diagnosed prevalence of 330,000, Lupus Nephritis with 90,000, Systemic Sclerosis with 100,000 and Myositis with 70,000[63] ALLO-316 - The TRAVERSE Ph1 trial supports the potential of ALLO-316 in CD70+ RCC, with encouraging activity in solid tumors and FDA RMAT designation[64] - ASCO 2025 will feature the next Ph1b data update for ALLO-316[65] - The TRAVERSE addressable population creates a >$3.5 billion global market opportunity[65, 97] Financial Position - Allogene has a strong financial position with $335.5 million in cash, cash equivalents, and investments at the end of Q1 2025, projecting runway into 2H 2027[78]

Summary of Allogene's Earnings Call Company Overview - **Company**: Allogene Therapeutics - **Focus**: Development of CAR T-cell therapies, specifically the Alpha-three study of Semacell for frontline consolidation in DLBCL (Diffuse Large B-cell Lymphoma) patients Key Points and Arguments Study Execution and Enrollment - The Alpha-three study is a pivotal Phase 2 randomized study focusing on patients who are MRD (Minimal Residual Disease) positive after frontline R-CHOP treatment [3][4] - Over 250 patients have consented to undergo MRD testing, indicating strong demand for the study [9][10] - The study's first milestone has been pushed to the first half of 2026 due to initial delays in patient enrollment and site activation [5][39] Patient Selection and Testing - The study targets patients who have completed R-CHOP but remain MRD positive, with an expected conversion rate of 20% for MRD positivity among those tested [13][94] - Most patients consenting for MRD testing have already started R-CHOP treatment, which lasts approximately 18 weeks [14][17] Study Design and Regulatory Considerations - The study design is unique as it focuses on frontline consolidation, which has not been previously established [4][6] - The FDA has shown support for the study design, which is recognized by hematologists and the investor community [4][39] - The primary endpoint of the study is event-free survival, not MRD conversion, although MRD conversion will be used for internal decision-making [86][88] Safety and Efficacy - The study will monitor safety, particularly looking for any imbalances in safety compared to the observation arm [46][47] - Previous Phase I data indicated a 60% complete response rate, with 100% in patients with low-volume disease [54][56] - The study aims to demonstrate that MRD negativity correlates with prolonged event-free survival, with existing data suggesting that MRD negative patients have a significantly lower chance of recurrence [92][94] Future Considerations - The interim analysis will assess safety and efficacy, with a focus on how many MRD positive patients convert to MRD negativity [47][79] - The study is designed to be statistically powered, with plans to enroll approximately 240 patients [80][81] - The potential for MRD-based stratification to become a standard endpoint in future studies is acknowledged, indicating a shift in the field towards this approach [119][121] Additional Important Insights - The conversation highlighted the challenges of educating patients about MRD testing and the implications of being MRD positive [26][28] - There is a recognition of the need for transparency with investors regarding study timelines and performance [39][40] - The discussion also touched on the broader implications of MRD testing in the context of CAR T therapies and the evolving landscape of treatment options for lymphoma patients [115][117]

Summary of the Conference Call Company and Industry - The conference call involved **Arcelix**, a company in the **biotechnology** sector, specifically focusing on therapies for **multiple myeloma**. Core Points and Arguments 1. **Data Release and Efficacy**: Arcelix presented data from their **IMGIGINE-one** registrational trial, highlighting a **68% complete response rate** with a median follow-up of **12.5 months**. This positions their therapy, **anitosella**, as a leading option in the myeloma community [5][7][8]. 2. **Safety Profile**: The company emphasized that no cases of delayed events, such as **Parkinsonism** or **enterocolitis**, have been observed, suggesting a superior safety profile compared to competitors like **Carvicti** [8][9][16]. 3. **Manufacturing and Scalability**: Kite is responsible for manufacturing, and the company is confident in their ability to deliver the product reliably and at scale, with manufacturing times within the commercial specifications of **14 to 17 days** [41][42]. 4. **Regulatory Filing Timeline**: Arcelix aims for a **BLA filing** by mid to late **2026**, with productive discussions with the FDA ongoing [36][39]. 5. **Market Positioning**: The company plans to differentiate its launch strategy from previous CAR T therapies by ensuring better availability and reliability, addressing physician concerns about therapy access [43][44]. Additional Important Content 1. **Comparison with Competitors**: The company believes that the safety and efficacy data do not support the notion of a class effect among CAR T therapies, indicating that their product is distinct [9][19][31]. 2. **Patient Enrollment Challenges**: It was noted that excluding patients with peripheral neuropathy from trials would be impractical, as a significant percentage of patients experience this condition post-treatment [24]. 3. **ALC Monitoring**: The company does not monitor **Absolute Lymphocyte Count (ALC)** as a treatment intervention but captures it for analysis. They believe that ALC levels do not correlate directly with safety profiles as suggested by competitors [21][51][54]. 4. **Future Data Updates**: The next data update is expected at the **ASH** conference in December, which will provide additional follow-up data [34]. This summary encapsulates the key points discussed during the conference call, focusing on the company's product, its competitive advantages, and future plans in the biotechnology sector.

Summary of Gilead Sciences (GILD) 2025 Conference Call Company Overview - **Company**: Gilead Sciences (GILD) - **Focus**: CAR T franchise, specifically the development of a new BCMA CAR T therapy for myeloma Key Points Efficacy and Safety of BCMA CAR T Therapy - **Efficacy Data**: - Average follow-up of 12.6 months shows a high overall response rate of 97% and a complete response (CR) rate of 68% [3][4] - Minimal residual disease (MRD) rate is reported at 93% [3] - **Safety Profile**: - Grade 3 or above CRS or ICANS events are at 1% or less, indicating a favorable safety profile [4][5] - No delayed neurotoxicity, such as parkinsonism or Guillain-Barré syndrome, has been observed [5][6] Manufacturing and Production - **Manufacturing Facilities**: - Three manufacturing facilities are operational, with production for clinical trials occurring at the Maryland facility [7][8] - Aiming for 96% reliability in turnaround times comparable to existing products like Yescarta and TACARTIS [9][15] - **Tech Transfer**: - Successful tech transfer with no reported issues, allowing for efficient production processes [16][18] Market Opportunity and Patient Access - **Target Population**: - Launching into the fourth-line plus population for myeloma, where currently only 10% of eligible patients receive CAR T therapy [20][21] - Emphasis on outpatient therapy to increase patient access, as 90% of myeloma patients are treated in community settings [21][22] - **Authorized Treatment Centers**: - Currently have 555 authorized treatment centers globally, with plans for expansion by the time of product launch in 2026 [25] Competitive Landscape - **Market Challenges**: - Facing competition from new entrants in the CAR T space and T cell engagers, leading to a 22% decline in the TACARTICE franchise [29] - Despite challenges, lymphoma segment grew by 2% [30] Future Developments - **New Constructs**: - Development of bisistronic constructs targeting CD19 and CD20, with a focus on improving efficacy and safety [40][42] - Plans to expand into autoimmune diseases and solid tumors, with ongoing studies in conditions like lupus and glioblastoma [50][52] Regulatory and Data Expectations - **Regulatory Strategy**: - Engaging with regulatory agencies for the submission of data from ongoing studies, including the IMGIGN-one trial [13] - **Upcoming Data Releases**: - Anticipated data presentations at ASCO and EHA, including updates on new constructs and manufacturing improvements [38][52] Additional Insights - **Patient-Centric Approach**: - Emphasis on reaching patients in community settings and exploring outpatient treatment options to alleviate hospital capacity issues [22][24] - **Innovative Manufacturing Techniques**: - Implementation of automation and rapid sterility testing to enhance production efficiency [34][36] This summary encapsulates the critical insights from the Gilead Sciences conference call, highlighting the company's strategic focus on CAR T therapies, manufacturing capabilities, market opportunities, and future developments.

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $21.8 million, down from $24.5 million in Q1 2024, aligning with the higher end of guidance [7][10] - Gross margin decreased to 56% from 60.3% in the previous year [8][14] - Operating loss was $49.7 million compared to a loss of $2.3 million in Q1 2024, primarily due to a goodwill impairment charge of $48 million [8][10] - Adjusted EBITDA was $800,000, down from $1.6 million in Q1 2024 [15] - Cash flow from operations improved to $3 million from $1.4 million in the prior year [16] Business Line Data and Key Metrics Changes - Revenue in The Americas declined 9.4% year-over-year and 5.4% sequentially [11] - European revenue decreased 29% sequentially and 9% year-over-year [12] - APAC revenue increased 6.6% sequentially but was down 17% compared to the prior year [13] Market Data and Key Metrics Changes - The Americas faced a slowdown attributed to budget clarity issues for academic and NIH funding [11] - European sales were impacted by a lack of seasonal bump and lower CRO sales [12] - APAC market showed slight sequential growth but anticipated challenges due to tariff announcements [13] Company Strategy and Development Direction - Focus on expanding adoption of new products while reducing costs, with an expected reduction in operating expenses by an additional $1 million per quarter starting Q2 2025 [25] - New product introductions include the SOHO telemetry devices and VivaMARS system, targeting both academic and industrial customers [19][20] - Emphasis on bioproduction applications and exploring partnerships for CAR T therapy production [21][31] Management's Comments on Operating Environment and Future Outlook - Management expressed concerns over NIH funding and the impact of tariffs on revenue, particularly in China [25][53] - Positive outlook on the adoption of organoid systems due to government policy changes encouraging alternative testing methods [24][34] - Anticipated Q2 revenue guidance is between $18 million to $20 million, with gross margin expected to be in the 55% to 57% range [25] Other Important Information - Goodwill impairment charge of $48 million was recorded due to a decrease in market capitalization [10][29] - Net debt decreased to $30.8 million, reflecting improved cash flow management [16] Q&A Session Summary Question: Can you elaborate on the impairment charge? - Management explained that the impairment was due to a drop in market cap, necessitating a reassessment of goodwill, leading to a non-cash charge of $48 million [29] Question: What about the bioproduction business and CAR T therapy? - Management confirmed that the BTX system is being adopted by a domestic biotech for CAR T therapy production, indicating strong traction in the market [31] Question: How is the MEA product line performing amid NIH funding uncertainties? - Management noted strong interest in the MEA product line, particularly from academic researchers, despite a slowdown in purchasing processes due to NIH staffing changes [34][45] Question: What are the refinancing plans? - Management indicated that refinancing will be more expensive than commercial rates, with terms likely spanning four to five years [46][48]

Financial Data and Key Metrics Changes - The company reported recognized revenue of $9 million for Q1 2025, marking a strong start for the U.S. launch of Ocassel [8][42] - Cost of sales totaled $18 million, which includes costs for all commercial products delivered to authorized treatment centers [44] - The net loss for Q1 2025 was $70.2 million, compared to a net loss of $52.7 million for the same period in 2024 [46] Business Line Data and Key Metrics Changes - The company aims to increase the number of centers authorized to deliver Ocassel from 39 to approximately 60, targeting 90% access to patients across the U.S. [11] - Research and development expenses decreased to $26.7 million from $30.7 million in the same period in 2024, primarily due to cost shifts following the approval of Ocassel [44] Market Data and Key Metrics Changes - As of April 1, CMS published codes for inpatient and outpatient use for Ocassel, formalizing reimbursement for patients on government programs [9][43] - The company is preparing for market expansion in the UK and Europe, having received conditional marketing authorization from the MHRA in the UK [12] Company Strategy and Development Direction - The company plans to expand its market share for CAR T products and is exploring opportunities in acute lymphoblastic leukemia and pediatric populations [12][14] - The strategy includes a fast-to-market approach for lupus nephritis, focusing on a refractory patient population with a clear objective endpoint [36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the initial momentum seen in Q1 and expects this to carry into the second quarter [10] - The company is well-capitalized with $516.6 million in cash and equivalents, which supports ongoing commercialization efforts [46][52] Other Important Information - The company is evaluating the implications of the April 1 coding update on revenue recognition policies [57] - The safety profile of Ocassel is favorable, with no high-grade cytokine release syndrome observed in patients [19] Q&A Session Summary Question: Can you clarify the revenue recognition for Ocassel? - Management confirmed that revenue recognition for Q1 was based on patients receiving both doses, and they are evaluating the implications of the new coding update [54][56] Question: What is the potential exposure to UK or pharma-specific tariffs? - Management noted that blood products are typically exempt from tariffs, but the final impact remains uncertain pending government announcements [60][62] Question: Can you provide details on the cost of goods sold (COGS) for the quarter? - Management indicated that the majority of COGS is driven by the cost of products sold and those delivered but not yet booked as sales, with smaller contributions from patient assistance programs [71][73] Question: What is the median turnaround time for manufacturing success? - Management reported that the turnaround time is tracking towards the target of 16 days, consistent with previous trials [86]

Financial Data and Key Metrics Changes - The company reported recognized revenue of $9 million for Q1 2025, marking a strong start for the U.S. launch of Ocassel [7][42] - Cost of sales totaled $18 million, which includes costs for all commercial products delivered to authorized treatment centers [43][44] - Research and development expenses decreased to $26.7 million from $30.7 million in the same period in 2024, primarily due to cost shifts following Ocassel's approval [44] - Selling, general, and administrative expenses increased to $29.5 million from $18.2 million in the same period in 2024, driven by increased headcount for U.S. commercialization [45] - The net loss for Q1 2025 was $70.2 million, compared to $52.7 million for the same period in 2024 [46] Business Line Data and Key Metrics Changes - The company is focusing on expanding the number of centers authorized to deliver Ocassel therapy from 39 to approximately 60, aiming for 90% patient access across the U.S. [9][11] - The company is also planning to present key updates based on long-term follow-up from the FELIC study, which is expected to provide encouraging data for Ocassel [10] Market Data and Key Metrics Changes - As of April 1, CMS published codes for Ocassel, formalizing reimbursement for patients on government programs, which is expected to enhance market access [7][43] - The company has received conditional marketing authorization from the MHRA in the UK and is engaging with NICE for reimbursement processes [11] Company Strategy and Development Direction - The company aims to increase the number of treatment centers and expand market share for CAR T products, with a focus on geographic expansion into the UK and Europe [11][12] - The company is exploring the utility of its products in earlier stages of treatment and in pediatric populations, with plans for investigator-sponsored trials [13][14] - The company is also looking into opportunities beyond acute lymphoblastic leukemia, targeting a broader range of B cell malignancies and autoimmune diseases [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the initial momentum seen in Q1 and expects this to carry into Q2 [8] - The company is well-capitalized with $516.6 million in cash and equivalents, which is expected to support the launch and commercialization of its products [46][52] - Management highlighted the importance of medical need in regulatory assessments and the potential for accelerated access to therapies [66] Other Important Information - The company is preparing for updates and data presentations for various studies, including the Carlyle study for lupus nephritis and a phase I study for progressive MS [47][48] - The company is also evaluating the implications of recent coding updates on revenue recognition policies [56] Q&A Session Summary Question: Revenue recognition for Ocassel and impact of coding update - Management confirmed that revenue recognition for Q1 was based on patients receiving both doses, and they are evaluating the implications of the April 1 coding update on revenue recognition [54][56] Question: Potential exposure to tariffs - Management noted that blood products are typically exempt from tariffs, and the customs value used for tariff calculations is linked to manufacturing costs rather than product sales [61][62] Question: Manufacturing turnaround time and success rate - Management indicated that the turnaround time is tracking towards the target of 16 days, and while it is premature to discuss success rates, initial results indicate good quality products [87][88]